The EXIST-3 trial was a randomized, double-blind, placebo-controlled phase 3 study assessing the efficacy and safety of the mTOR inhibitor everolimus as adjunctive therapy for treatment-resistant focal seizures in TSC [64]. This evidence concerns the gene MTOR and tuberous sclerosis.